The verdict
Our read at a glance.
Which tirzepatide claims are supported by FDA-regulated Mounjaro/Zepbound labels and direct human trials, and where broader claims rely on surrogate, non-label, comparator, or product-identity-uncertain evidence.
- The signal
- SURPASS supports type 2 diabetes claims, SURMOUNT supports obesity and maintenance claims, and SURMOUNT-OSA supports obstructive sleep apnea with obesity. SUMMIT, SYNERGY-NASH, kidney/cardiorenal analyses, and semaglutide comparator studies are important public evidence lanes, but they remain population-, endpoint-, and label-specific.
- The unknown
- Long-term post-market safety, discontinuation and maintenance patterns, cardiovascular and kidney outcome translation, liver and HFpEF regulatory direction, and whether comparator findings hold across real-world populations without becoming a ranking claim.
- Our read
- One of the strongest Watchlist entries for defined medical contexts, but still a boundary lesson: labels, trial populations, endpoints, and product identity determine what the evidence can and cannot say.
The explainer
Watch the 18:29 explainer.
9.7K views · Jun 2026
The mechanism
How it works.
Tirzepatide is a synthetic peptide that activates two incretin receptors at once, GIP and GLP-1. Through the GLP-1 receptor it increases satiety in the brain, slows gastric emptying, raises glucose-dependent insulin release, and lowers glucagon when glucose is high; the added GIP-receptor activity contributes further to insulin signaling and fat-tissue metabolism. These are established human effects that support its approved use in type 2 diabetes, weight management, and obstructive sleep apnea with obesity.
Safety & regulatory boundary
The consequential part.
Approved-product evidence applies to FDA-regulated Mounjaro and Zepbound labels, not compounded, fraudulent, counterfeit, research-use, imported, internet-market, or identity-uncertain products. FDA has said unapproved GLP-1 versions are not reviewed for safety, effectiveness, or quality before marketing, the tirzepatide shortage was resolved on 2024-12-19, and the 2026 503B bulks-list action is a proposal, not a final determination.
What's next
What we're watching.
Full cardiovascular, kidney, liver, HFpEF, sleep-apnea, maintenance, and comparative-effectiveness publications; regulator decisions on non-label evidence lanes; counterfeit and unapproved-product warnings; and post-market signal interpretation that separates reports from incidence or causation.
Context
Why this is discussed.
Tirzepatide is one of the clearest examples of a metabolic therapy moving from glucose control into obesity and obesity-related disease outcomes, while also showing how quickly approved-product evidence gets blurred with compounded, counterfeit, imported, or internet-market claims.
The evidence base
72 cited references.
Regulatory & labels24
National Library of Medicine / FDA label · Updated 2026-04-22
National Library of Medicine / FDA label · Updated 2026-04-22
Food and Drug Administration · 2022-05-13
Food and Drug Administration · 2022
FDA Center for Drug Evaluation and Research · 2022
Food and Drug Administration · 2023-11-08
Food and Drug Administration · 2023-11-08
Food and Drug Administration · 2024-12-20
FDA Center for Drug Evaluation and Research · 2025-12-19
Food and Drug Administration · 2026-01-13
Food and Drug Administration · 2025-02-21; updated 2026-04-01
Food and Drug Administration · 2024-12-19
Food and Drug Administration · Current page checked 2026-05-16
Food and Drug Administration · 2026-02-06
Food and Drug Administration · 2026-03-03
Food and Drug Administration · 2026-04-30
Food and Drug Administration · 2025
European Medicines Agency · Current page checked 2026-05-16
Health Canada · 2026-01-21
Medicines and Healthcare products Regulatory Agency · 2026
Therapeutic Goods Administration · 2026-03-02
Therapeutic Goods Administration · 2025-12-01
National Institute for Health and Care Excellence · 2024/2025
National Institute for Health and Care Excellence · Last reviewed 2026-05-11
Registered trials7
ClinicalTrials.gov · NCT04255433
ClinicalTrials.gov · NCT04184622
ClinicalTrials.gov · NCT05412004
ClinicalTrials.gov · NCT04847557
ClinicalTrials.gov · NCT04166773
ClinicalTrials.gov · NCT05556512
ClinicalTrials.gov · NCT06047548
Indexed literature (PubMed)41
Rosenstock et al. · 2021
SURPASS-2 investigators · 2021
Ludvik et al. · 2021
Del Prato et al. · 2021
Dahl et al. · 2022
Rosenstock et al. · 2023
Inagaki et al. · 2022
Gastaldelli et al. · 2022
Heerspink et al. · 2022
SURPASS-4 investigators · 2023
SURPASS-CVOT investigators · 2024
SURPASS-CVOT investigators · 2026
Jastreboff et al. · 2022
Garvey et al. · 2023
Wadden et al. · 2023
Aronne et al. · 2024
SURMOUNT-CN investigators · 2024
SURMOUNT-J investigators · 2025
SURMOUNT-1 investigators · 2025
SURMOUNT-1 investigators · 2025
SURMOUNT-1 investigators · 2024
SURMOUNT-5 investigators · 2025
SURMOUNT-OSA investigators · 2024
Malhotra et al. · 2024
SURMOUNT-OSA investigators · 2026
SURMOUNT-OSA investigators · 2025
SUMMIT investigators · 2024
SUMMIT investigators · 2025
SUMMIT investigators · 2025
SUMMIT investigators · 2025
SUMMIT investigators · 2025
JAMA authors · 2025
Loomba et al. · 2024
SYNERGY-NASH investigators · 2024
SYNERGY-NASH investigators · 2025
SYNERGY-NASH investigators · 2025
Almansour et al. · 2025
Liu et al. · 2024
Caruso et al. · 2024
Chen et al. · 2025
Meta-analysis authors · 2024
Keep reading